Table 3 Bispecific mAb Directed Against HLA Class I and CD55 Enhance C3 Deposition on HeLa Cells

From: The Inhibitory Effect of CD46, CD55, and CD59 on Complement Activation After Immunotherapeutic Treatment of Cervical Carcinoma Cells with Monoclonal Antibodies or Bispecific Monoclonal Antibodies

mAb/bispecific mAb (μg/ml) directed against

C3c (MESF)

CD55

54a

HLA Class I

101

HLA Class I and CD55 (20)

286

HLA Class I and CD55 (2)

211

HLA Class I and CD55 (0.2)

112

HLA Class I*CD55 (200)

567

HLA Class I*CD55 (20)

361

HLA Class I*CD55 (2)

124

HLA Class I*CD55 (0.2)

109

  1. Experiments were performed as described in “Material and Methods.” Results of a representative experiment are shown.
  2. aC3 deposition depicted in MESF-values (×104).
Back to article page